Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM.

Gastroenterology. 2013 Apr;144(4):829-40. doi: 10.1053/j.gastro.2013.01.001. Epub 2013 Jan 4.

2.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

3.

Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.

Gao Q, Zhao YJ, Wang XY, Guo WJ, Gao S, Wei L, Shi JY, Shi GM, Wang ZC, Zhang YN, Shi YH, Ding J, Ding ZB, Ke AW, Dai Z, Wu FZ, Wang H, Qiu ZP, Chen ZA, Zhang ZF, Qiu SJ, Zhou J, He XH, Fan J.

Gastroenterology. 2014 May;146(5):1397-407. doi: 10.1053/j.gastro.2014.01.062. Epub 2014 Feb 4.

PMID:
24503127
4.

Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma.

Li L, Lian B, Li C, Li W, Li J, Zhang Y, He X, Li Y, Xie L.

PLoS One. 2014 Jun 4;9(6):e98653. doi: 10.1371/journal.pone.0098653. eCollection 2014.

5.

Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.

Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, Qin LX, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang ZY, Thorgeirsson SS, Wang XW.

Hepatology. 2012 Nov;56(5):1792-803. doi: 10.1002/hep.25890. Epub 2012 Aug 22.

6.

Genetic profiling of intrahepatic cholangiocarcinoma.

Andersen JB, Thorgeirsson SS.

Curr Opin Gastroenterol. 2012 May;28(3):266-72. doi: 10.1097/MOG.0b013e3283523c7e. Review.

7.

Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma.

Dalmasso C, Carpentier W, Guettier C, Camilleri-Broët S, Borelli WV, Campos Dos Santos CR, Castaing D, Duclos-Vallée JC, Broët P.

BMC Cancer. 2015 Mar 14;15:126. doi: 10.1186/s12885-015-1111-6.

8.

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM.

Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.

9.

Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.

Talabnin C, Janthavon P, Thongsom S, Suginta W, Talabnin K, Wongkham S.

Hum Pathol. 2016 Jun;52:47-54. doi: 10.1016/j.humpath.2015.12.027. Epub 2016 Feb 1.

PMID:
26980022
10.

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

Sia D, Villanueva A, Friedman SL, Llovet JM.

Gastroenterology. 2017 Mar;152(4):745-761. doi: 10.1053/j.gastro.2016.11.048. Epub 2016 Dec 30. Review.

PMID:
28043904
11.

Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.

Xue TC, Zhang BH, Ye SL, Ren ZG.

Tumour Biol. 2015 Aug;36(8):5891-9. doi: 10.1007/s13277-015-3261-1. Epub 2015 Feb 26.

PMID:
25712376
12.

Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.

Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D'Onofrio M, Iacono C, Scarpa A, Guglielmi A.

Ann Surg Oncol. 2016 May;23(5):1699-707. doi: 10.1245/s10434-015-5046-6. Epub 2015 Dec 30.

PMID:
26717940
13.

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.

Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C.

Gut. 2003 May;52(5):706-12.

14.

Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.

Shi JY, Xing Q, Duan M, Wang ZC, Yang LX, Zhao YJ, Wang XY, Liu Y, Deng M, Ding ZB, Ke AW, Zhou J, Fan J, Cao Y, Wang J, Xi R, Gao Q.

Oncotarget. 2016 Jan 19;7(3):2867-77. doi: 10.18632/oncotarget.6558.

15.

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.

Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM.

Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3.

16.

Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma.

Zhang C, Bai DS, Huang XY, Shi GM, Ke AW, Yang LX, Yang XR, Zhou J, Fan J.

PLoS One. 2013;8(1):e54619. doi: 10.1371/journal.pone.0054619. Epub 2013 Jan 22.

17.

Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.

Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A.

Exp Mol Pathol. 2015 Oct;99(2):344-53. doi: 10.1016/j.yexmp.2015.08.003. Epub 2015 Aug 8.

PMID:
26260902
18.

Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.

Bergeat D, Fautrel A, Turlin B, Merdrignac A, Rayar M, Boudjema K, Coulouarn C, Sulpice L.

J Surg Res. 2016 Jun 15;203(2):441-50. doi: 10.1016/j.jss.2016.03.044. Epub 2016 Mar 26.

PMID:
27363654
19.

Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Tong WM, Jia JD, Huang J.

PLoS One. 2013 Dec 13;8(12):e82426. doi: 10.1371/journal.pone.0082426. eCollection 2013.

20.

Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.

Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I.

Mod Pathol. 2014 Jan;27(1):73-86. doi: 10.1038/modpathol.2013.112. Epub 2013 Jul 5.

Supplemental Content

Support Center